Qure Ventures
Qure Ventures is a venture capital firm based in Herzliya, Israel, founded in 2012. It is notable for being Israel's first fund exclusively focused on digital health. The firm is led by experienced professionals from the digital health sector who have a track record of founding, growing, and exiting companies over the past two decades. Qure Ventures primarily invests in startups located in Israel, leveraging the country's prominent tech and digital health ecosystem. The firm has established strategic partnerships with key stakeholders across various domains, including consumers, providers, payers, and pharmaceuticals, which facilitates rapid access to market and clinical trial opportunities for its portfolio companies. Additionally, Qure Ventures benefits from the global network and medical expertise of its parent company, OurCrowd, enhancing its deal access and due diligence capabilities.
CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.
CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.